132 related articles for article (PubMed ID: 37699075)
1. Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment.
Sanfilippo R; Sbaraglia M; Fabbroni C; Croce S; Ray-Coquard I; Guermazi F; Paolini B; Blanc-Durand F; Lecesne A; Chiappa V; Dei Tos AP; Casali PG
Clin Cancer Res; 2023 Nov; 29(22):4679-4684. PubMed ID: 37699075
[TBL] [Abstract][Full Text] [Related]
2. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.
Oduyebo T; Rauh-Hain AJ; Meserve EE; Seidman MA; Hinchcliff E; George S; Quade B; Nucci MR; Del Carmen MG; Muto MG
Gynecol Oncol; 2014 Feb; 132(2):360-5. PubMed ID: 24296345
[TBL] [Abstract][Full Text] [Related]
3. Oncological outcomes of unexpected uterine leiomyosarcoma: A single-center retrospective analysis of 5528 consecutive hysterectomies.
Casarin J; Ghezzi F; Lembo A; Artuso V; Schivardi G; Galati EF; Ambrosoli AL; Bogani G; Multinu F; Cromi A
J Surg Oncol; 2024 Mar; 129(3):517-522. PubMed ID: 37974522
[TBL] [Abstract][Full Text] [Related]
4. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
[TBL] [Abstract][Full Text] [Related]
5. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
6. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic value of Bcl-2 in uterine leiomyosarcoma.
Travaglino A; Raffone A; Raimondo D; Gencarelli A; Esposito I; Gallo C; Improda FP; Vitale SG; Mollo A; Casadio P; Seracchioli R; Zullo F; Insabato L
Arch Gynecol Obstet; 2023 Feb; 307(2):379-386. PubMed ID: 35344084
[TBL] [Abstract][Full Text] [Related]
8. Low-grade smooth muscle tumors of the primary and the secondary mullerian system: a proposed concept of multicentricity.
Posligua L; Silva EG; Deavers MT; Merino MJ; Malpica A
Int J Gynecol Pathol; 2012 Nov; 31(6):547-55. PubMed ID: 23018207
[TBL] [Abstract][Full Text] [Related]
9. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.
Dhingra S; Rodriguez ME; Shen Q; Duan X; Stanton ML; Chen L; Zhang R; Brown RE
Int J Clin Exp Pathol; 2010 Jan; 4(2):134-46. PubMed ID: 21326806
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
[TBL] [Abstract][Full Text] [Related]
12. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.
Cybulska P; Sioulas V; Orfanelli T; Zivanovic O; Mueller JJ; Broach VA; Long Roche KC; Sonoda Y; Hensley ML; O'Cearbhaill RE; Chi DS; Alektiar KM; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2019 Aug; 154(2):333-337. PubMed ID: 31200927
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
[TBL] [Abstract][Full Text] [Related]
14. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
[TBL] [Abstract][Full Text] [Related]
15. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study.
Bizzarri N; Ghirardi V; Di Fiore GLM; De Iaco P; Gadducci A; Casarin J; Perrone AM; Pasciuto T; Scambia G; Fagotti A
Int J Gynecol Cancer; 2019 Sep; 29(7):1134-1140. PubMed ID: 31420411
[TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.
Lusby K; Savannah KB; Demicco EG; Zhang Y; Ghadimi MP; Young ED; Colombo C; Lam R; Dogan TE; Hornick JL; Lazar AJ; Hunt KK; Anderson ML; Creighton CJ; Lev D; Pollock RE
Ann Surg Oncol; 2013 Jul; 20(7):2364-72. PubMed ID: 23334251
[TBL] [Abstract][Full Text] [Related]
17. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
18. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
Ip PP; Cheung AN; Clement PB
Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
[TBL] [Abstract][Full Text] [Related]
19. Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma.
Abedin Y; Gabrilovich S; Alpert E; Rego E; Begum S; Zhao Q; Heller D; Einstein MH; Douglas NC
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682660
[TBL] [Abstract][Full Text] [Related]
20. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
